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ABSTRACT 
Background 
The most common complication after endovascular aneurysm repair (EVAR) is continued 
perfusion of the aneurysmal sac, known as endoleak. Assessment of markers released from the 
aneurysm wall into the circulation has been suggested as a possible alternative for detecting 
endoleaks. The aim of this meta-analysis was to examine if circulating concentrations of matrix 
metalloproteinase (MMP)-9 were higher in patients with endoleak after EVAR. 
Methods  
A systematic search of the MEDLINE, EMBASE, Scopus, Web of Science and Cochrane 
Library Databases was conducted. Studies reporting circulating MMP-9 concentrations in 
patients who did and did not have endoleaks after EVAR that met inclusion and exclusion 
criteria were included. A meta-analysis using a random effects model was performed to assess 
the association between circulating concentrations of MMP-9 and endoleak. Sensitivity analyses 
were performed using the one-study remove approach. Study quality was assessed using a 
quality assessment tool.  
Results 
Prior to EVAR, plasma concentrations of MMP-9 were similar in patients that did and did not 
subsequently develop an endoleak (Standardised mean difference: -0.13; 95% confidence 
interval, -0.63-0.37, p=0.60). 1 month after EVAR, plasma concentrations of MMP-9 were non-
significantly higher in patients that had an endoleak (Standardized mean difference: 0.56; 95% 
CI -0.02-1.15, p = 0.06). 3 months after EVAR, plasma concentrations of MMP-9 were higher in 
patients that had an endoleak (Standardised mean difference: 1.42; 95% confidence interval, 
0.48-2.36, p<0.003).  
Conclusions 
This meta-analysis suggests that plasma MMP-9 concentrations measured 3 months after EVAR 
are higher in patients that have an endoleak. It remains to be established whether plasma MMP-9 
testing is sufficiently accurate for use as a surveillance test for endoleak after EVAR.  
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
 
INTRODUCTION 
The global mortality attributable to aortic aneurysm rupture is estimated as 2.78 per 100,000 
person years, which represents an 11% increase over the last 20 years.1 The only recognized 
treatment for aortic aneurysm is surgical repair which is predominantly performed using stent 
grafts placed inside the aorta, i.e. endovascular aortic aneurysm repair (EVAR). The most 
common complication of EVAR is residual perfusion of the aneurysmal sac known as endoleak. 
Endoleak can be defined into 5 main types. Residual blood flow into the aneurysm sac occurring 
proximal or distal to site of the graft attachment is known as Type 1.  Reverse flow through 
aortic branches, such as visceral, lumbar or thoracic arteries, into the aneurysm sac are known as 
type 2 endoleaks and are the most common type. Type 3, 4 and 5 endoleaks are due to graft 
defects, graft porosity and endotension, respectively, and are rare. Due to the frequent occurrence 
of endoleaks patients undergo long term surveillance after EVAR with computed tomographic 
angiography (CTA) and ultrasound imaging. A number of potential problems are associated with 
the use of these imaging modalities. CTA necessitates contrast administration and radiation 
exposure, posing a problem in patients with impaired renal function and also exposing the 
patients to a small increased risk of malignancy. Ultrasound, while eliminating the problem of 
contrast and radiation exposure, requires experienced sonographers and is accepted to not be as 
accurate as CTA. The use of both these imaging modalities require trained staff and 
appropriately equipped facilities which may pose a problem to patients based remotely or 
regionally. The use of these modalities for surveillance also reduces the cost effectiveness of 
EVAR. 
A number of circulating biomarkers have been reported to be associated with the presence of 
aortic aneurysm, such as markers of thrombosis, inflammation and matrix degradation.2  Matrix 
metalloproteinases (MMPs) are soluble, zinc-dependent enzymes with elastolytic activity and are 
produced by a range of cells including macrophages and smooth muscle cells. MMPs, 
particularly MMP-9, have been implicated in the development of aneurysms through 
extracellular matrix degradation leading to structural changes in the aortic wall which stimulates 
excessive positive remodeling.3 Release of MMP-9 into the circulation has been suggested as a 
biomarker for abdominal aortic aneurysm (AAA) presence, progression and complications of 
AAA repair. Continued perfusion of the aneurysm sac in individuals with endoleak is postulated 
to promote MMP-9 release into the circulation.4 
The objective of this meta-analysis was to evaluate whether circulating concentrations of matrix 
metalloproteinase (MMP)-9 were higher in patients who developed endoleak compared to 
patients who did not have an endoleak after EVAR. 
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METHODS 
Literature Search 
A search strategy was devised according to the 2009 Preferred Reporting Items of Systematic 
Reviews and Meta-Analyses (PRISMA) statement.5 An electronic search of the databases 
MEDLINE, EMBASE, SCOPUS, Web of Science and Cochrane Library Databases was 
performed from inception to December 2014 with no language restrictions on 25th November 
2014. To identify studies investigating plasma levels of MMPs and the presence of endoleak 
after EVAR, the following search terms were applied: (‘Endovascular repair of aortic aneurysm’ 
OR ‘EVAR’)[Title/Abstract] AND (‘endoleak’)[Title/Abstract] AND (‘biomarker*’ OR ‘MMP’ 
OR ‘matrix metalloproteinase’)[Title/Abstract]. The database search was supplemented by a 
search of the reference lists of included studies as well as utilizing the related articles function 
provided in each database. Titles and abstracts were screened to identify potentially relevant 
studies. If the suitability of an article was uncertain, the full text article was reviewed. All 
potentially relevant studies were subsequently assessed by review of the full text articles. 
Eligible studies were those that assessed MMP-9 levels and endoleak in patients who had 
undergone EVAR of aortic aneurysms. Included studies utilized CTA in the identification of 
endoleak. Studies were excluded if animal studies were involved; there was no clear division of 
patients into endoleak and non-endoleak groups; endovascular repair of aneurysms involving 
arteries other than the aorta was performed; and if the assessment of circulating blood markers 
did not include MMP-9. Review articles were also excluded. 
 
Data extraction 
Data extraction was performed according to a predefined form and recorded in tables. All data 
was reviewed independently by 2 authors (E.N and D.R.M) and cross-checked in a consensus 
meeting. Any discrepancies were resolved through discussion. The following data were obtained 
from the included studies: Study author, year and design, study sample size, individual study 
inclusion and exclusion criteria, population characteristics, definitions used for endoleak, type of 
aneurysm repaired, number and type of stent grafts used,  number of endoleaks, MMP-9 assay 
used, mean concentration and variance of circulating plasma MMP-9 concentrations in patients 
with and without endoleak, imaging modality for detection of endoleak, the timing of imaging 
after EVAR and the timing of blood collection for MMP-9 measurements after EVAR. If blood 
samples were collected at multiple time points, then all measured MMP-9 concentrations were 
recorded. Authors of eligible studies were contacted for additional information when required. 
Quality Assessment 
The quality and potential bias of included studies were assessed by 2 of the authors (E.N, 
D.R.M). A modified quality assessment form was derived using elements from the Newcastle 
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Ottawa Scale and Cochrane collaboration tool for assessment of the risk of bias.6-7 This form is 
summarised in Supplementary Table 1 and a discussion is provided in the Appendix.  
Statistical Analysis 
A meta-analysis was performed comparing plasma MMP-9 concentrations in blood samples 
obtained preoperatively, 1 month after EVAR and 3 months after EVAR in patients with and 
without an endoleak identified during follow-up. These time points were chosen as they were 
each reported in three or more eligible studies. Three studies8,9,10 reported MMP-9 levels as 
means and standardized deviation (s.d.) and two studies11,12 reported means and standard error. 
All data was imported into Review Manager (Revman, Version 5.2, Copenhagen; The Nordic 
Cochrane Centre, Copenhagen, Denmark). Standard deviations were calculated automatically by 
the Revman software for studies that reported standard error only. Standardised mean differences 
(SMDs) and 95% confidence intervals (CI) were calculated for each included study. Study 
specific estimates were combined using inverse-variance weighted average of logarithmic SMDs 
in a random-effects model. The random-effects model was chosen to assess heterogeneity on the 
summary statistics. Inter-study heterogeneity was assessed by means of the I2 index. I2 values of 
>50% were accepted to denote statistical heterogeneity. Sensitivity analyses were performed 
using the one-study-removal approach to assess the contribution of each study to the pooled 
estimate6 (Supplementary table 4). This was achieved by excluding individual studies one at a 
time and recalculating the pooled SMD estimates for the remaining studies. Publication bias was 
assessed by constructing funnel plots of the logarithm of effect size versus the standard error, 
however, accurate appraisal was not possible due to the limited number of studies.  
 
RESULTS 
Study selection 
Initial database searches yielded fifteen potentially eligible studies after removal of duplicates 
(Figure 1). No additional studies were identified by hand-searching the reference lists. A total of 
seven studies were excluded based on review of their titles and abstracts. The most common 
reasons for exclusion were failure to measure MMP-9 concentrations or identify endoleaks in 
patients who had undergone EVAR. 
Of the eight studies8-15 reporting plasma MMP-9 concentrations in patients who had been 
investigated for endoleak after EVAR, three studies were excluded based on analysis of their full 
text.13,14,15 One study was a review article which was excluded as defined in our exclusion 
criteria.13 One study reported no identified endoleaks even though MMP-9 concentrations were 
measured.14 One study reported endoleaks but did not report values for MMP-9 concentrations 
and data could not be obtained from contacting the authors.15 
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Study characteristics 
Ultimately five studies8-12 were included in this meta-analysis (Figure 1). Of the included studies, 
two studies were conducted in the United States10,11, one study in Italy8, one in the Netherlands9 
and one in Japan12. All studies were hospital based and consisted of either vascular surgical 
inpatients or individuals presenting to a vascular clinic for follow-up. The design of the included 
studies are outlined in Table 1 and a summary of each individual study findings is provided in 
Table 2. Four of the studies included were prospective cohort studies8,9,10,11 and one study was a 
non-randomized control trial12. Four studies9-12 involved AAA patients while 1 study8 involved 
thoracoabdominal aneurysm patients. The average age of the studied patients ranged from 66 to 
76 years. There were no significant differences in the sex of patients that had and did not have an 
endoleak in all studies. All studies8-12 provided baseline characteristics of patients including at 
least age, gender and vascular comorbidities. Sample sizes of the included studies ranged from 4 
to 17 patients with an endoleak and 13 to 23 patients with no endoleak. Overall the studies 
selected in this meta-analysis included a total of 127 patients, of whom 40 had endoleaks 
identified on CT imaging. The types of endoleaks included type 1 (n=12), type 2 (n=27) and type 
3 (n=1). In one study11, although there were 8 endoleaks, identified samples were only available 
for 5 patients for assessment of MMP-9 levels.  Therefore, a total of 37 endoleaks were included 
in the meta-analysis. 
Seven different types of stent grafts were used in the 4 studies8,10,11,12 that provided data 
including Ancure Guidant (16), Gore Excluder (25), Talent World Medical (39), AneuRx 
Medtronic (6), Vanguard (7), Cook Zenith (13) and custom made Malmo-Ivancev, consisting of 
a non-crimped Dacron graft handsewn to a tapered Gianturco stent with Goretex sutures (3). One 
study did not state the type of stent grafts used9. 
All studies8-12 measured plasma MMP-9 levels as a primary outcome measure. In addition to 
MMP-9 levels, two studies8,10 measured MMP-3 concentrations, two studies8,9 measured tissue 
inhibitor of metalloproteinase (TIMP-1) and one study [9] measured MMP-2 levels. Given the 
limited number of studies investigating these two circulating markers, a meta-analysis was only 
conducted for MMP-9. 
All studies8-12 used different commercially available ELISA assays to estimate plasma MMP-9. 
Three studies8,10,11 used an assay from Amersham UK; one study12 used an assay from SRL Inc, 
Japan and one study [9] used an assay from GE Healthcare, Sweden. Four of the studies8,10,11,12 
reported the protocol for MMP-9 measurement. Two studies10,11 reported the within assay (<6%) 
and between assay precision (<10%) while the remaining three studies8,9,12 did not report assay 
variability. 
Plasma MMP-9 levels were assessed at a variety of time points. All five studies8-12 reported 
MMP-9 values at 3 months after EVAR (Table 3). One study11 also reported the trend in MMP-9 
levels in patients with and without endoleak. Two studies11,12 measured plasma MMP-9 levels 
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prior to EVAR, 1 month and 3 months after EVAR. Two studies8,10 measured plasma MMP-9 
levels prior to EVAR, 1 month, 3 months and 6 months after EVAR. One study9 did not define 
the time point for measurement of MMP-9. 
All studies8-12 utilized CTA in the diagnosis of endoleak. The time points used for CTA 
surveillance imaging for endoleak was variable across studies. One study11 performed CTA at 
the time of discharge, 1 and 3 months after EVAR. One study10 performed CTA at the onset of 
new symptoms and at 6 months after EVAR. One study8 performed CTA on discharge, 1 and 6 
months after EVAR. One study12 performed CTA at 3 and 12 months after EVAR. One study9 
did not report when CTA was performed. 
Mean follow up time was variable across studies, ranging from 6 to 25 months. Only two studies 
8,10
 reported clear follow up time periods. The remaining three studies9,11,12 did not report the 
follow up times even though plasma MMP-9 measurements and surveillance CTA were 
conducted at variable time points after EVAR. 
All studies8-12 reported significantly higher MMP-9 levels in patients with endoleak when 
compared to patients without endoleak at various timepoints. Two studies8,12 reported higher 
plasma MMP-9 levels in patients that had an endoleak compared to patients that had no endoleak 
at 1 month after EVAR. Three studies8,11,12 reported higher plasma MMP-9 levels in patients that 
had an endoleak compared to patients with no endoleak at 3 months after EVAR. One study10 
reported higher plasma MMP-9 levels in patients that had an endoleak at 6 months after EVAR.  
One study8 reported higher plasma MMP-9 levels in patients that had an endoleak at 1 month, 3 
months and 6 months after EVAR. One study9 did not state when plasma MMP-9 levels were 
measured but noted higher plasma MMP-9 levels in patients who had endoleaks when compared 
to patients without endoleaks. 
One study9 assessed the sensitivity and specificity of plasma MMP-9 in detecting endoleak 
presence by use of a receiver operating characteristic curve and reported sensitivity of 100% and 
specificity of 96% at a cutoff MMP-9 value of 55.18ng/ml. 
Study Quality  
None of the studies were graded as good according to predefined quality criteria. Three 
studies8,10,11 were graded as average while the other two remaining studies9,12 were graded as 
poor (Table 3 and Appendix).  
Data Synthesis 
Meta-analysis was performed to analyze MMP-9 concentrations prior to EVAR (4 
studies8,10,11,12), 1 month after EVAR (3 studies8,10,12) and 3 months after EVAR (5 studies8-12) 
according to the availability of data.  
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A meta-analysis of four studies8,10,11,12 consisting of 90 patients, 20 of whom developed an 
endoleak, found no significant differences in pre-operative plasma MMP-9 concentrations 
between patients who did and did not subsequently develop an endoleak (Figure 2; SMD: -0.14; 
95% CI -0.64-0.36, p=0.60). No significant heterogeneity was noted in these four studies (I2=0). 
A meta-analysis of three studies8,10,12 consisting of 72 patients, 15 of whom developed an 
endoleak showed a trend towards higher MMP-9 levels in patients with endoleak but this did not 
reach statistical significance (Figure 3; SMD: 0.56; 95% CI -0.02-1.15, p = 0.06). No significant 
heterogeneity was noted in these 3 studies (I2=0). 
A meta-analysis of all five studies8-12, consisting of 37 patients with endoleaks and 90 patients 
without endoleaks, demonstrated significantly higher plasma concentrations of MMP-9 in 
patients who developed endoleaks compared to those who did not 3 months after EVAR (Figure 
4; SMD: 1.42; 95% CI 0.48-2.36, p<0.003). There was evidence of heterogeneity across these 
studies (I2=75%) and the likelihood of publication bias could not be assessed due to the limited 
number of studies. Sensitivity analyses through the one-study-remove approach demonstrated 
that multiple studies contributed to the observed difference in plasma MMP-9 levels between the 
two groups and that exclusion of any one study did not substantively effect the overall result. 
 
DISCUSSION 
The number of studies which have investigated biomarkers concentrations prior to and after 
EVAR are limited. Our meta-analysis suggests that plasma MMP-9 levels are higher in patients 
that have endoleaks 3 months after EVAR compared to patients that have successful exclusion of 
their aneurysm. The meta-analysis also suggested that plasma MMP-9 concentrations were 
higher in patients with endoleaks 1 month after EVAR, however, the finding was of borderline 
significance (p=0.06), most likely due to the reduced sample size for this time point. It is 
postulated that continued perfusion of the aneurysmal sac in patients that have an endoleak 
perpetuates the aortic wall remodeling resulting in release of MMP-9 into the circulation.  
In contrast, our meta-analysis suggested that pre-operative plasma MMP-9 levels were not 
significantly different in patients who did and did not subsequently develop an endoleak. In four 
of the included studies8,10,11,12, it was reported that plasma MMP-9 levels declined after EVAR in 
patients with successful exclusion of their aneurysm. The time point after EVAR when blood 
samples were collected for MMP-9 measurement varied in the included studies. Pre-operative 
MMP-9 levels were compared with those measured in samples obtained between 1 and 6 months 
after EVAR.8-12 One study9 did not report baseline MMP-9 levels but reported significantly 
higher plasma MMP-9 levels in patients who had endoleak when compared to patients with no 
endoleak after EVAR. 
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At present CTA is the gold standard for detecting endoleaks after EVAR. CTA necessitates 
contrast administration and radiation exposure, posing a problem in patients with impaired renal 
function and also exposing the patients to a small increased risk of malignancy. Alternative 
forms of imaging used include ultrasound, contrast enhanced duplex ultrasound, MRI and 
nuclear imaging.16 The use of CTA as an imaging modality requires trained staff and 
appropriately equipped facilities which reduces the cost effectiveness of EVAR. 
An ideal biomarker for use in the detection of endoleaks would have high sensitivity to detect all 
true endoleaks as well as a high specificity to exclude individuals with no endoleak. The 
sensitivity and specificity of MMP-9 as a biomarker to detect endoleak was investigated in one 
of the included studies.9 The authors utilized a receiver operating characteristic curve to assess 
the sensitivity and specificity of plasma MMP-9 in detecting endoleaks. The study9 reported a 
sensitivity of 100% and a specificity of 96% at a cutoff MMP-9 value of 55.18ng/ml. This study9 
included only 37 patients and larger prospective studies are required to confirm the findings. It is 
possible that the use of MMP-9 might reduce the requirement for imaging after EVAR by 
limiting CTA to patients with concentrations above this or similar levels however this needs 
specifically investigating.  
The majority of endoleaks detected in this study were Type 2. Previously defined risk factors for 
endoleak include large aneurysm diameter, severe infrarenal neck angulation, short infrarenal 
neck length, the presence of concomitant iliac artery aneurysm, female sex, history of smoking, 
and hypertension.17-19 It has not been investigated whether plasma MMP-9 can differentiate 
between the various subtypes and degrees of endoleak. A biomarker for endoleak that is both 
qualitative and quantitative would be extremely useful especially with regards to directing 
subsequent intervention. Future studies could investigate the association between MMP-9 levels 
and type of endoleak. 
This meta-analysis has a number of limitations.  Overall study quality ranged from poor to 
average with significant heterogeneity between studies. There was variation in the time intervals 
used for assessment of endoleak and measurement of plasma MMP-9. Our finding of a higher 
plasma MMP-9 level in patients with endoleak was based on data reported at 3 months after 
EVAR. A uniform surveillance protocol would be useful in future studies to examine whether 
endoleaks detected at later follow-up stages are also associated with higher MMP-9 
concentrations. In additional, current practice for follow-up of EVAR now extends up to 10 
years. The maximal follow-up period in our meta-analysis post EVAR was 3 months and this 
limits conclusions that can be drawn due to the short length of follow-up.  
None of the included studies adjusted for potential confounding factors. It is possible that 
elevated MMP-9 levels in patients with endoleak could reflect another feature of these patients 
other than endoleak. It has been reported for example that greater systemic atherosclerosis 
increases the risk of endoleak and atherosclerosis itself is associated with higher circulating 
MMP-9 levels. Furthermore, one study12 involved administration of azelnidipine (a calcium 
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channel blocker) which may possibly contribute to a decrease in plasma inflammatory 
biomarkers including MMP-9. None of the studies adjusted for statin use, which has been 
associated with attenuation of MMP-9 activity in aortic aneurysmal tissue.20,21  
There was variability in the measurement of MMP-9 concentrations across studies. Three 
studies8,10,11 utilised the same assay from the UK while two other studies utilized assays from 
Sweden9 and Japan12.  Furthermore, MMP-9 exists as a secreted proenzymatic zymogen which is 
then cleaved into its active 82kDa form by peptidases and other MMPs. Both forms can be found 
in plasma. None of the studies in this meta-analysis defined exactly which form was measured. 
Therefore, it is impossible to ascertain which MMP-9 form was associated with endoleak after 
EVAR. 
Finally, there was a relatively small number of patients in all the included studies with a pooled 
total of only 127 patients. This limits the conclusions that can be drawn as a result. Yet, it is 
remarkable that MMP-9 levels were significantly elevated in all the included studies8-12, despite 
the small sample numbers. Larger clinical studies in which blood samples are collected at 
standardized time points and patients are prospectively included are needed to verify the findings 
of this meta-analysis. Studies are also needed to assess the association of other biomarkers with 
endoleak. 
CONCLUSIONS 
Studies investigating the relationship of plasma MMP-9 and endoleak after EVAR are limited to 
small poor quality studies. Even though this meta-analysis suggests that plasma MMP-9 
concentrations are higher in patients with endoleak 3 months after EVAR, further studies 
encompassing larger patient numbers with stringent reproducible protocols are needed to confirm 
these findings. 
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Figure Legends 
Figure 1: PRISMA flow diagram to illustrate selection of studies 
Figure 2. Meta-analysis of the association between plasma MMP-9 levels measured prior to 
EVAR and the development of endoleak. Forest plot illustrating mean MMP-9 concentrations 
with 95% CIs. The diamond represents the overall mean MMP-9 concentration calculated with a 
random effects model.  
Figure 3. Meta-analysis of the association between plasma MMP-9 levels and presence of 
endoleak measured 1 month after EVAR. Forest plot illustrating mean MMP-9 concentrations 
with 95% CIs. The diamond represents the overall mean MMP-9 concentration calculated with a 
random effects model. Higher levels of MMP-9 were demonstrated in patients with endoleak. 
Figure 4. Meta-analysis of the association between plasma MMP-9 levels and presence of 
endoleak measured 3 months after EVAR. Forest plot illustrating mean MMP-9 concentrations 
with 95% CIs. The diamond represents the overall mean MMP-9 concentration calculated with a 
random effects model. Higher levels of MMP-9 were demonstrated in patients with endoleak. 
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Table 1: Characteristics of the included studies 
Study Type of 
study 
Inclusion 
criteria Exclusion criteria 
Number 
of 
EVARs 
Number 
of 
endoleaks 
Aneurysm 
type 
Imaging 
surveillance 
protocol 
EVAR stent 
graft type 
Biomarkers 
measured 
Time 
between 
EVAR and 
MMP 
measurement 
Monaco et 
al, 2007[8] 
Prospective 
cohort 
Atherosclerotic 
TAA 
Aneurysmal 
diameter >6cm 
Documented 
aneurysmal 
growth more 
than 0.5cm in 
last 12 months 
 
Thoracic aortic dissection 
Thoracic aortic transection 
Marfan Syndrome 
Proximal aortic neck diameter 
>4.4cm 
Length of nonaneurysmal aorta 
from origin of left subclavian 
artery to proximal attachment site 
<1.5cm 
32 4 TAA 
CTA on discharge, 
1 month and 6 
months 
postoperatively 
Talent 
(Medtronic) 
MMP-9 
MMP-3 
TIMP-1 
Baseline 
1 month 
3 months 
6 months 
Hellenthal 
et al, 
2012[9] 
Prospective 
cohort Not stated Not stated 37 17 AAA 
CTA (period not 
stated) - 
MMP-9 
MMP-2 
TIMP-1 
Baseline 
18 months 
21 months 
Sangiorgi 
et al, 
2001[10] 
Prospective 
cohort 
Aneurysmal 
diameter >4cm 
Documented 
aneurysmal 
expansion 
>5mm in 12 
months 
Aortic neck diameter <20mm 
<1.5cm of nonaneurysmal 
infrarenal aorta at proximal 
attachment site 
Angulation of aorta >60 degrees 
Aberrant renal arteries 
Tortuosity or kinking of iliac 
vessels 
30 7 AAA 
CTA, 6 months 
postoperativelyand 
on onset of new 
symptoms 
Gore 
Excluder 
(n=16) 
Vanguard   
(n = 7) 
Talent 
World 
Medical      
(n = 7) 
MMP-9 
MMP-3 
 
Baseline 
1 month 
3 months 
6 months 
Lorelli et 
al, 2002[11] 
Prospective 
cohort 
All elective 
AAA 
Aneurysmal rupture 
Unwilling participants 25 8 AAA 
CTA, 1 month and 
3 month 
postoperatively 
 
CTA, before 
discharge and at 3 
months 
postoperatively  
(custom-made 
stent graft) 
AneuRx 
Medtronic  
(n = 6) 
Ancure 
Guidant      
(n = 16) 
Custom 
made 
Malmo-
Ivancev      
(n = 3) 
MMP-9 
Baseline 
1 month 
3 months 
Nakamura 
et al, 
2009[12] 
Non-
randomised 
RCT 
Atherosclerotic 
infrarenal true 
AAA with 
diameter > 
45mm 
Availability for 
followup 
Clinical/laboratory suspicion of 
infection 
Acute aortic dissection 
Traumatic aortic lesions 
Ruptured aneurysms 
Mycotic aneurysms 
CRF, on dialysis 
22 
 
4 
 
AAA 
CTA (preop, 3 
months and 1 year 
postoperatively) 
Cook Zenith 
(7 in 
azelnidipine, 
6 in control) 
Gore 
Excluder (5 
in 
MMP-9 
AAA 
diameter 
Baseline 
1 month 
3 months 
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Autoimmune disease 
Connective tissue disease 
Aortitis 
Neoplasms 
Immunodeficiencies 
Anti-inflammatories 
Chemotherapy/Immunosuppresant 
Indication for open surgery 
Difficulty in postoperative 
followup 
 
azelnidipine, 
4 in control) 
 
RCT: randomized controlled trial EVAR: endovascular aneurysm repair AAA: abdominal aortic aneurysm CTA: computed tomographic angiography MMP-2: 
matrix metalloproteinase-2 MMP-3: matrix metalloproteinase-3 MMP-9: matrix metalloproteinase 9 TAA: thoracic abdominal aneurysm TIMP-1 tissue 
inhibitor of metalloproteinase-1 CRF: chronic renal failure EVAR: endovascular repair of aneurysm MMP-9: matrix metalloproteinase-9 
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Table 2: Summary of included studies  
Study Study Design Selected Study Outcomes 
Monaco et al, 2007[8] 
 
Evaluation of plasma MMP-9, MMP-
3 and TIMP-1 levels in patients 
undergoing EVAR (32 vs 25 control) 
In patients who underwent EVAR without endoleak, plasma MMP-9 levels were not  significantly 
reduced postoperatively, at 1 month, 3 months and 6 months (p=NS) when compared to control group 
values. 
 
In patients who underwent EVAR with endoleak, mean plasma MMP-9 levels were significantly 
higher postoperatively (p<0.01), 1 month (p<0.001), 3 months (p<0.01) but not significantly increased 
at 6 months (p=NS) when compared to control group values. 
 
In patients who underwent EVAR with endoleak, mean plasma MMP-9 levels were higher at 1 month 
(P<0.02), 3 months (p<0.02) and 6 months (p<0.04), when compared to patients who underwent 
EVAR without endoleak 
Hellenthal et al, 
2012[9] 
 
Evaluation of plasma MMP-9 levels 
in patients undergoing EVAR 
In patients who underwent EVAR with endoleak, mean plasma MMP-9 levels were significantly 
higher when compared to patients who underwent EVAR with no endoleak (89.54+26.46ng/ml vs 
25.02+13.40ng/ml respectively, p<0.0001) 
Sangiorgi et al, 
2001[10] 
 
Evaluation of plasma MMP-9 and 
MMP-3 levels in patients undergoing 
open surgery or EVAR (15 vs 30) 
In patients who underwent EVAR, there were 7 cases of endoleak, 5 Type 1 and 2 Type 2. 
 
In patients who underwent open repair, mean plasma MMP-9 levels were significantly reduced from 
baseline (28.8+9.9ng/ml) at 6 months (14.7+6.6ng/ml, p<0.001) 
 
In patients who underwent EVAR without endoleak, mean plasma MMP-9 levels were significantly 
reduced from baseline (34.1+22.6ng/ml) at 6 months (14.6+7.0ng/ml, p<0.05) 
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In patients who underwent EVAR with endoleak, mean plasma MMP-9 levels were significantly 
increased from baseline (34.1+22.6ng/ml) at 6 months (44.3+20.7ng/ml, p<0.05) 
Lorelli et al, 2002[11] 
 
Evaluation of plasma MMP-9 levels 
in patients undergoing open surgery 
or EVAR (26 vs 25) 
In patients who underwent open repair, mean plasma MMP-9 levels were significantly increased from 
baseline (83.9+26.1ng/ml) at 1 month (149.5+40.1ng/ml, p<0.05) and remained elevated at 3 months 
(129.8+56.6ng/ml) 
 
In patients who underwent EVAR without an endoleak, mean plasma MMP-9 levels were significantly 
reduced from baseline (60.8+8.8ng/ml) at 3 months (27.4+5.2ng/ml, p<0.05) 
 
In patients who underwent EVAR with endoleak, mean plasma MMP-9 levels were not significantly 
reduced from baseline (53.0+11.2ng/ml) at 3 months (67.1+26.7ng/ml, p= NS) 
Nakamura et al, 
2009[12] 
 
Evaluation of plasma MMP-9 in 
patients undergoing EVAR 
randomized to receive azelnidipine 
and control (12 v 10) 
 
 
In patients who underwent EVAR, there were 4 cases of endoleak (Type 2), 3 in azelnidipine, 1 in 
control 
 
In patients with no endoleaks after EVAR, mean plasma MMP-9 levels decreased significantly (from 
39.5+14.3ng/ml to 25.0+12.6, p = 0.004) and 3 months (28.2+10.2ng/ml, p = 0.004) 
 
In patients with endoleaks, no significant reduction in mean plasma MMP-9 from baseline 
(37.5+9.0ng/ml) at 1 month (26.8+8.4ng/ml) and 3 months (38.5+15.7ng/ml) 
 
In the azelnidipine group without endoleaks, mean plasma MMP-9 decreased significantly from 
baseline (47.7+13.2ng/ml) after 1 month (26.6+12.8ng/ml, p<0.001) and 3 months (26.1+11.4ng/ml, 
p<0.001) 
 
In the control group without endoleaks, no significant reduction in mean plasma MMP-9 was noted 
from baseline (31.3+10.5ng/ml) at 1 month (33.4+12.1ng/ml) and 3 months (30.3+9.1ng/ml) 
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Table 3: Mean MMP-9 plasma levels (ng/ml) in patients with and without endoleak at 3 months after EVAR 
 
Study 
Endoleak No endoleak Weighted 
mean (%) 
Standardised 
Mean 
Difference 
p value Assay Brand Mean SD Total Mean SD Total 
Monaco et 
al, 2007[8] 130.3 32.2 4 70.4 46.2 16 16 
1.30 
(0.11,2.48) 0.03 
Amersham, 
UK 
Hellenthal 
et al, 2012[9] 89.5 25.5 17 25.0 13.4 20 29 
3.09  
(2.10, 4.08) 0.00001 
GE 
Healthcare, 
Sweden 
Sangiorgi 
et al, 
2001[10] 
40.2 20.9 7 23.6 10.4 23 24 1.21  (0.30, 2.12) 0.009 
Amersham, 
UK 
Lorelli et 
al, 2002[11] 53.0 25.0 5 27.4 18.7 13 14 
1.19  
(0.07, 2.31) 0.04 
Amersham, 
UK 
Nakamura 
et al, 
2009[12] 
38.5 31.4 4 28.2 43.3 18 17 0.24  (-0.85, 1.32) 0.67 
SRL Inc, 
Japan 
Overall - - 37 - - 90 100 1.42  (0.48, 2.36) 0.003 - 
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Quality Assessment  
Study quality was assessed in relation to the reporting of the following items within the publications of the included studies: 1) study design and 
setting and whether the primary outcome measures were related directly to MMP-9 concentrations and the presence of endoleak; 2) definition of 
the endoleak and control groups; 3) methods of patient recruitment, definition of inclusion and exclusion criteria and baseline characteristics of 
the patients; 4) assay type, protocol and quality of assay results for measuring MMP-9 concentrations (such as assay precision and interassay 
coefficient of variation) and 5) adjusting, excluding or matching for confounders. Quality was scored as shown in Supplementary Table 1 and 
graded as poor, average or good according to Supplementary table 2. Individual study grading is summarized in Supplementary table 3. No 
studies were excluded due to poor methodological quality. In the studies8,10,11 that were graded as average, there was a clear study design, good 
reporting of baseline participant characteristic, primary outcome, assay protocol and variability but poor or no adjustment for confounders. In the 
studies9,12 that were graded as poor, there were unclear definitions of baseline participant characteristics, poor reporting of the outcome of 
interest and no adjustment for confounders.  
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Supplementary table 1: Quality assessment questions 
Quality category Explanatory Questions Response 
Yes No Unclear 
Did the study investigate the main 
primary outcome? 
Does the study investigate MMP-9 levels in patients with and without endoleaks?    
Is the study defined according to study type (case-control, RCT etc)    
Is the study setting defined (e.g. hospital based; single/multi-centred)?    
Is the study population sample well-
defined? 
 
Is the recruitment of participants conducted in a geographically defined region?    
Are the methods for recruitment/sampling detailed in the study?    
Are inclusion and exclusion criteria detailed?    
Are controls appropriately matched to the cases (i.e. minimum gender and age)?    
Are the baseline characteristics of patients detailed?    
Did the study define the groups for 
comparison adequately? 
 
Was the definition of endoleak in patients adequately defined?    
Was the diagnosis of endoleak in patients adequately defined (type of imaging 
used)? 
   
Are the controls defined properly? 
 
Was the negative diagnosis (no endoleak) adequately defined? How was the negative 
diagnosis defined? 
   
Was the time period for diagnosis for no endoleak defined in the study?    
Was MMP-9 level measured by specific Was the assessment of MMP-9 one of the main study aims?    
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defined methods? 
 
Does the study report on plasma or serum MMP-9 (blood medium)?    
Does the study detail the assay method used for assessment of MMP-9?    
Does the study detail the protocol used for MMP-9 measurement (incl. blood 
collection and blood medium used; eg. plasma, serum, whole blood)?  
   
Did the study report on the quality of MMP-9 assay results? (e.g. assay precision, 
interassay coefficient of variation) 
   
Did the study report on timeline of measurement of MMP-9 levels?    
Did the study exclude, match or adjust 
for the following confounders as listed? 
 
Age?    
Gender?    
BMI?    
Hypertension?    
Smoking status?    
Diabetes?    
Presence of or renal function?    
Presence of CVD?    
COPD?    
Use of other medications?    
Previous vascular surgery?    
Previous endoluminal access?    
Does this study show any publication 
biases? 
Does the study report findings in relation to the original aims?    
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 Does the study report findings in the context of the existing literature? (Study 
rationale) 
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Supplementary table 2: grading system for studies 
Quality category Poor Average Good 
Study design Less than 1 criteria met 1-2 criteria met 3 of 3 criteria met 
Participant characteristics Less than 2 criteria met 2-3 criteria met At least 4 of the 5 criteria met 
Endoleak cases and definition Less than 1 criteria met 1 of 2 criteria met 2 of 2 criteria met 
Control cases definition Less than 1 criteria met 1 of 2 criteria met 2 of 2 criteria met 
MMP-9 measurement Less than 3 criteria met 3 -4 criteria met At least 5 of the 6 criteria met 
Confounders Less than 1 criteria met 2 of 12 criteria met (age and gender) At least 3 of 12 criteria met 
Publication bias Less than 1 criteria met 1 of 2 criteria met 2 of 2 criteria met 
Total Less than 16 16-24 More than 24 
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Supplementary table 3: Quality assessment table (consensus) 
Quality category Monaco et al. (2007)[8] 
Hellenthal et al. 
(2012)[9] 
Sangiorgi et al. 
(2001)[10] 
Lorelli et al. 
(2002)[11] 
Nakamura et al. 
(2009)[12] 
Study design Good (3) Average (2) Average (2) Average (2) Average (2) 
Participant characteristics Good (4) Poor (1) Good (4) Average (3) Good (4) 
Endoleak definition Good (2) Average (1) Good (2) Good (2) Good (2) 
Control-cases definition Average (1) Average (1) Good (2) Good (2) Poor (0) 
MMP-9 measurement Good (5) Average (3) Good (6) Good (6) Good (5) 
Confounders Poor (0) Average (2) Poor (0) Poor (0) Poor (0) 
Publication bias Good (2) Good (2) Good (2) Good (2) Good (2) 
Total score 17 12 18 17 15 
Overall grade Average Poor Average Average Poor 
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Supplementary table 4: Sensitivity analysis using one study removal approach  
Study Removed Standardized mean difference P value 
None 1.42 (0.48,2.36) 0.003 
Monaco[8] 1.44 (0.27,2.62) 0.02 
Hellenthal[9] 0.99 (0.46,1.52) 0.0002 
Sangiorgi[10] 1.47 (0.23,2.71) 0.02 
Lorelli[11] 1.47 (0.29,2.65) 0.01 
Nakamura[12] 1.71 (0.76,2.66) 0.0004 
 
 
 
 
